Select Pharmaceuticals Portfolio
Filed by Fidelity Select Portfolios. What this fund reported holding in its latest quarterly NPORT-P. Positions are ordered by share of the fund rather than by size, because that is what separates a conviction from a rounding error.
What it holds
Largest share of the fund first.
| Company | % of fund | Value |
|---|---|---|
| LLYEli Lilly and Co | 24.47% | $399.8M |
| GSKGSK plc | 7.92% | $129.5M |
| MRKMerck & Co Inc | 6.37% | $104.1M |
| VTRSViatris Inc | 5.46% | $89.2M |
| BMYBristol-Myers Squibb Co | 4.61% | $75.4M |
| GILDGilead Sciences, Inc | 4.47% | $73.1M |
| ELANElanco Animal Health Inc | 4.26% | $69.6M |
| MRNAModerna Inc | 3.20% | $52.2M |
| BNTXBiontech SE | 1.71% | $28M |
| JNJJohnson & Johnson | 0.96% | $15.7M |
| NTLAIntellia Therapeutics Inc | 0.91% | $14.8M |
| AXSMAxsome Therapeutics Inc | 0.76% | $12.4M |
| AMLXAmylyx Pharmaceuticals Inc | 0.53% | $8.7M |
| ARWRArrowhead Pharmaceuticals Inc | 0.33% | $5.4M |
| IONSIonis Pharmaceuticals Inc | 0.15% | $2.4M |
Source: NPORT-P filings, via EDGAR. Positions arrive by CUSIP, and only a CUSIP verified against a ticker is kept — so this is what we could match, not everything the fund holds, and the matched value is therefore below the fund's own size. A balance is shares where the filing says `NS` and a principal amount where it says `PA`, which is why it is not labelled shares in both cases.
Follow Select Pharmaceuticals Portfolio by email
Select Pharmaceuticals Portfolio's new holdings reports, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.